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Abstract
Background and purpose: Unlike squamous carcinomas, breast adenocarcinoma may be as sensitive to fraction size as
late dose-limiting normal tissues. If so, fewer larger fractions would be as safe and effective as regimens based on 2.0 Gy
fractions. The first step is to test the effects of radiotherapy fractions O2.0 Gy on late normal tissue responses in the
breast after tumour excision and radiotherapy for early breast cancer.
Patients and methods: One thousand four-hundred and ten women with T1-3 N0-1 M0 invasive breast cancer were
randomised between 1986–98 into one of three radiotherapy regimens after local tumour excision of early stage breast
cancer; 50 Gy in 25 fractions (F) vs two dose levels of a test schedule giving 39 or 42.9 Gy in 13 F over 5 weeks. Fraction
sizes were 2.0, 3.0 and 3.3 Gy, respectively. The primary endpoint was late change in breast appearance compared to
post-surgical appearance scored from annual photographs blinded to treatment allocation. Secondary endpoints included
palpable breast induration (fibrosis) and ipsilateral tumour recurrence.
Results: After a minimum 5-year follow up, the risk of scoring any change in breast appearance after 50 Gy/25 F,
39 Gy/13 F and 42.9 Gy/13 F was 39.6, 30.3 and 45.7%, from which an a/b value of 3.6 Gy (95% CI 1.8–5.4) is estimated.
The a/b value for palpable breast induration was 3.1 Gy (95% CI 1.8–4.4).
Conclusions: An a/b value of around 3 Gy for late normal tissue changes in the breast is derived from the estimated
equivalence of 41.6 Gy in 13 fractions and 50 Gy in 25 fractions over 5 weeks, in line with trial predictions.
q 2005 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology 75 (2005) 9–17.
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radiotherapy is based on the assumption that larger fraction
sizes cause a steeper rise in the rate of late adverse effects
than in the rate of tumour control, with inevitable
compromise of the therapeutic ratio. The relationship
between fraction size and tissue response is well described
by the a/b value in the linear quadratic model of
fractionation sensitivity [10]. According to this empirical
model, low a/b values signify greater sensitivity to fraction
size than higher a/b values. In squamous cell carcinomas of
the head and neck and cervix uteri, indirect estimates yield
high a/b values of R7 Gy for tumour control, compared to
2–5 Gy for late normal tissue responses [3]. These estimates
support the choice of 2.0 Gy fractions for the treatment
of squamous cell carcinoma, for example. However,
experimental data suggest that other human tumour types0167-8140/$ - see front matter q 2005 Elsevier Ireland Ltd. All rights researe significantly more sensitive to fraction size than
squamous carcinomas [16,17]. Specifically, a/b values of
4–5 Gy have been derived for the radiation response of
recurrent or inoperable breast cancer [6,8]. Values of 1.8–
2.0 Gy have been reported for the local control of soft tissue
sarcoma [7,15]. There are also suggestions that prostate
carcinoma is more sensitive to fraction size than previously
thought [5]. These estimates suggest that low fractionation
sensitivity may not be a uniform characteristic of human
cancers. If breast adenocarcinoma is as sensitive, or almost
as sensitive, to fraction size as dose-limiting normal breast
tissues, including skin, adipose tissue, glandular tissue,
muscle and perhaps bone, this has obvious implications for
the optimal choice of radiotherapy regimen. If shorter
schedules delivering fewer, larger fractions are as, or more,
effective than conventional regimens, they will be morerved. doi:10.1016/j.radonc.2005.01.005
Fractionation sensitivity and dose response10convenient for patients, provided the total dose is adjusted
better than in the past to the tolerance of non-target tissues
[1,9].
Against this background, a randomised clinical trial was
started in 1986 to test the fractionation sensitivity of breast
tissues to modest increases in fraction size above 2.0 Gy.
The trial was controlled for overall treatment time and was
designed to generate reliable estimates of a/b for late
changes in breast appearance and induration. It was not
powered to generate reliable estimates of a/b for tumour
control, nor to address patient-oriented functional out-
comes and quality of life. The preliminary results of this
‘pilot trial’ informed the design of the UK Standardisation of
Radiotherapy (START) trial launched in January 1999, and
the tumour control data from the pilot trial were incorpor-
ated into the START trial dataset. The START trial of 4451
patients includes a similar randomisation with tumour
control as the primary endpoint and patient self-assessments
of functional outcome and quality of life as important
secondary endpoints. The independent START Trial Steering
Committee has authorised the full publication of the late
radiotherapy normal tissue effects of the pilot trial, the
subject of this manuscript [12,21].Methods
Patients
Between January 1986 and March 1998, 1410 patients
were enrolled in a clinical trial of radiotherapy dose
schedules at the Royal Marsden Hospital (RMH), Sutton and
the Gloucestershire Oncology Centre (GOC), Cheltenham.
Patients with operable invasive breast cancer (T1-3 N0-1 M0)
requiring radiotherapy were eligible for the trial provided
they were under 75 years at presentation, had breast
preserving surgery and complete macroscopic resection of
invasive carcinoma. All patients had level II/III axillary
dissection, except for women at RMH over 50 years of age
with impalpable axillary lymph nodes, in whom a policy of no
axillary surgery or lymphatic radiotherapy was offered, and
some women at GOC who had axillary sampling [11]. Patients
with positive axillary pathology were recommended radio-
therapy to the supraclavicular fossa at RMH, but at GOC it
was reserved for patients with heavy node involvement in
levels I and II or any involvement in level III. At neither
institution was axillary radiotherapy given after axillary
dissection, although it was recommended after axillary
sampling if the axillary nodes were pathologically positive
and at GOC if no axillary surgery had been undertaken. The
use of adjuvant systemic therapy was not specified in the
protocol, and evolved over the accrual period according to
changes in routine local practice. In general, between 1986
and 1990, adjuvant tamoxifen 20 mg daily was prescribed for
a minimum of 2 years to women over the age of 50 years,
regardless of oestrogen receptor status. After 1990, women
%50 years were also recommended adjuvant tamoxifen
20 mg daily for 5 years. Between 1986 and 1990, adjuvant
CMF chemotherapy was recommended after surgery and
delivered either prior to radiotherapy or concurrently with
radiotherapy to all women %50 years with pathologically
positive axillary lymph nodes. After 1990, an increasingproportion of women aged 50–70 years with positive axillary
lymph nodes were offered adjuvant chemotherapy in
addition to endocrine therapy.Trial design, entry procedure and follow-up
Patients were randomised to three alternative dose
schedules delivered over 5 weeks at a ratio of 1:1:1. The
control arm of 50 Gy in 25 fractions over 5 weeks was
compared with 2 dose levels of an experimental schedule
delivering 13 fractions over 5 weeks (treating five times per
fortnight viz. Monday, Wednesday, Friday, Tuesday, Thurs-
day, etc.). The choices of fraction size for the 2 experimen-
tal arms were determined by the lower and upper limits of
fraction size considered to be equivalent, in terms of late
normal tissue responses, to 50 Gy in 25 fractions of 2.0 Gy.
Fraction sizes of 3.0 and 3.3 Gy were selected, correspond-
ing to a/b values of 1.8 and 6.0 Gy, respectively.
Randomisation was achieved by a telephone call to the
Clinical Trials and Statistics Unit at the Institute of Cancer
Research, Sutton after obtaining informed consent. Patients
were stratified by treatment centre and by whether
microscopic foci of invasive or intraduct disease was present
at or close (!3 mm) to the nearest surgical margin. In
patients with a complete microscopic resection, when the
clinician felt it was appropriate and the patient consented, a
sub-randomisation to boost versus no boost was performed.
This sub-randomisation closed in May 1994, and thereafter,
all patients were offered an elective boost. Patients were
reviewed 3-monthly to 3 years, 6-monthly to 5 years and
annually thereafter. Prospective physician assessments were
recorded annually on a trial proforma, including normal
tissue effects for 10 years in the first 806 patients.
Photographs were taken annually for the first 5 years and
then at 10 years in all evaluable patients. Patients agreed to
the annual photographic assessments as part of the research.Radiotherapy
Patients were simulated and treated in the same supine
position, at RMH with both arms abducted and at GOC with
one arm abducted. Patients at RMH were planned with the aid
of a conventional simulator, whereas patients at GOC were
planned using a simulator with axial tomographic facility.
During this era, clinicians planned patients by marking 50%
field borders on the skin a minimum 1 cm outside palpable
breast. Megavoltage photons (6 MV X-rays) were used, except
for a minority of small-sized patients treated with Co60 g-rays
or 4 MV X-rays and large-sized patients treated with 10 MV X-
rays. Wedge tissue compensators were used in all patients,
with the wedge angles estimated from a single transverse
external contour through the central plane. During the trial
period, lung corrections were applied at GOC, but not at RMH.
The reference point for tangential fields was in the centre of
the breast, midway between the skin entry points of the
tangential fields and midway between a perpendicular line
from the skin surface to the lung/chest wall interface. The
range of doses on the central plane was maintained between
K5 and C7% of the reference isodose, but 3D dose
compensation was not applied. No bolus was applied to
the excision scar. When delivered, lymphatic radiotherapy
comprised an anterior field to the supraclavicular fossa, using
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applied dose. If the axilla was included, an equally weighted
posterior axillary field was treated with every fraction to
ensure that 100% of the prescribed dose was delivered to the
axillary midline.
In all patients allocated to receive a boost, this was
delivered by electrons to the tumour bed to a dose of 14 Gy
to the 90% isodose (15.5 Gy to 100%) in 7 daily fractions.
Definition and assessment of endpoints
The primary endpoint was late change in breast appear-
ance compared to post-surgical appearance scored from
annual photographs blinded to treatment allocation. Sec-
ondary endpoints included palpable breast induration
(fibrosis) and ipsilateral tumour recurrence.
Photographic assessments of the breast
Frontal photographs of both breasts were taken after
primary surgery, before radiotherapy, and repeated annually
for 5 years and then at 10 years under standard conditions in
the photographic departments of both hospitals. Two
photographs were taken, one with the hands resting on the
hips, the other with the arms raised above the head. Follow-
up photographs were terminated in the case of local
recurrence, further breast surgery, declining health or
patient refusal.
In 7 dedicated assessment sessions over the 17-year
period, photographs were scored by 3 observers (2 male
clinicians and 1 female nurse) blind to patient identity,
fractionation allocation and year of follow-up. Comparisons
were always based on photographs at two time-points, one
showing postoperative appearance and the other showing
breast appearance at year n (nZ1–5, 10). Changes in the
contralateral breast made it possible to distinguish radio-
therapy effects from other time-related changes, e.g. weight
gain. Change in breast appearance compared with the
postoperative baseline was scored by each observer, acting
independently, on a 3-point graded scale (none/minimal, 0,
mild, 1, marked, 2) based on change in breast size, shrinkage
and shape. Breast size and surgical deficit were also scored
from the baseline photographs using 3-point graded scales.
Telangiectasia was ignored for the purpose of scoring
photographic changes (it was recorded on trial proformas at
annual follow-up).
All discrepancies between observers were re-evaluated
with an additional random subset (approximately 10%) to
investigate repeatability. After the repeat assessment, the
modal category was chosen if the observers were still in
disagreement. In the case of missing assessments, reason for
non-availability was classified as death, too ill (metastatic
disease or other concurrent illness) or patient declined
(including those unavailable due to change of residence),
local recurrence (patient no longer assessable), and missing
(administrative error).
Clinical assessments of the breast and arm
At annual follow-up clinic visits, the attending clinician
completed a trial proforma recording breast shrinkage,
distortion, oedema, induration, telangiectasia, arm swelling
and shoulder stiffness, each on 4-point graded scales (none,0, mild, 1, moderate, 2, marked, 3). Patient weight was not
recorded. Assessments of breast cosmesis were also made
(excellent, good, fair, poor). Over the period of the trial, the
number of clinicians, including specialist trainees, complet-
ing the trial proformas is estimated to be several dozen. In
the later years of the trial, the proforma was simplified for
new patients and the physician assessments were omitted.
Therefore, only patients randomised before this change are
available for inclusion in the analysis of the clinical
assessment data (806 patients).
Statistical methods
Photographic assessments of the breast
Time from baseline to first recording of ‘any radiation
effect’ (grade 1 or 2) and the time until ‘marked radiation
effect’ (grade 2) were calculated. Missing data at interven-
ing years were ignored. The probability of not developing
late radiation damage by each year of follow-up was
depicted over the follow-up period on a survival curve, and
the fractionation schedules compared using the Logrank
test. Kaplan–Meier estimates of the probability of no late
radiation damage at 5 and 10 years were obtained, with 95%
confidence intervals (CI). Other methods of analysing
interval-censored data were explored and found to produce
very similar results (data not shown). Cox proportional
hazards regression models were fitted in order to obtain
direct estimates (with 95% CI) of the a/b ratio for any change
and marked change in breast appearance.
Inter and intra observer variability was monitored by
comparing photographic scores between observers and also
by assessing the reproducibility of scores for each observer
by re-assessing a random sample of photographs. Degree of
agreement was assessed using a weighted kappa statistic,
where the weights were inversely related to the size of
differences between grades scored (i.e. equal grades receive
highest weight and grades differing by two categories
receive lowest weight).
The analysis was restricted to those patients who had at
least one follow-up and a baseline photograph with which to
compare subsequent changes (1202 patients). Absence of a
baseline photograph was usually due to administration
problems and did not appear to be related to fractionation
schedule.
Clinical assessments of the breast and arm
Analysis of the annual physician assessments was by
calculating time from baseline to first recording of an event,
using a method very similar to that used for the photographic
endpoint. The time to significant change, defined as grade 2
or 3 (moderate or marked), was calculated. Missing data at
intervening years were ignored. Survival curves showing the
probability of not experiencing a given event by each year of
follow-up were obtained. Kaplan–Meier estimates of the
probability of no late radiation damage at 5 and 10 years
were obtained, with 95% confidence intervals. Fractionation
schedules were compared using the Logrank test. Due to
analysis of multiple endpoints and the inflated risks of
observing statistically significant effects that reflect the play
of chance, emphasis was given to the most marked effects.
Fractionation sensitivity and dose response12Cox proportional hazards regression models were fitted in
order to obtain direct estimates (with 95% CI) of the a/b
ratio for the various clinical endpoints of late radiation
effect. The analysis of this endpoint was restricted toTable 1
Demographic and clinical characteristics of 1410 patients
randomised
Patient characteristic Number (%)
Age at randomisation
20–29 9 (0.9)
30–39 98 (7.0)
40–49 316 (22.4)
50–59 503 (35.7)
60–69 425 (30.1)
70–79 59 (4.2)
Breast size (from photographs)
Small 186 (13.2)
Medium 952 (67.5)
Large 203 (14.4)
Not known 69 (4.9)
Surgical deficit (from photographs)
Small 845 (59.9)
Medium 415 (29.4)
Large 76 (5.4)
Not known 74 (5.2)
cT stage
T0 59 (4.2)
T1 749 (53.1)
T2 575 (40.8)
T3 22 (1.6)
T4 2 (0.1)
TX 3 (0.2)
cN stage
N0 1187 (84.7)
N1 219 (15.5)
N2 3 (0.2)
NX 1 (0.1)
Number of nodes pathologically involved
0 564 (67.3)
1-3 202 (24.1)
4C 72 (8.6)
No axillary surgerya 572 (40.6)
Adjuvant treatment
None 289 (20.5)
Tamoxifen only 918 (65.1)
Chemotherapy only 40 (2.8)
TamoxifenCchemotherapy 156 (11.1)
Other 7 (0.5)
Axillary/SCFb treatment
None 337 (23.9)
Axillary/SCF RTc, no axillary surgery 231 (16.4)
Surgery, no RT 782 (55.5)
Surgery and SCF RT 59 (4.2)
Not known 1 (0.1)
Breast boost
Randomised to no boost 359 (25.5)
Randomised to boost 364 (25.8)
Non-randomised boost given 687 (48.7)
a cN0 and over 50 years.
b Supraclavicular fossa.
c Radiotherapy.the cohort of patients with detailed clinical assessment data
(nZ806).Results
Patient characteristics and follow-up
The demographic and clinical characteristics of the 1410
patients randomised into the trial are shown in Table 1. The
mean age of patients was 54.5 years (SD 9.7; range 25–78
years). Almost all (93.9%) of patients were stage cT1 or cT2,
and 67.3% of patients who underwent axillary staging were
node negative. The majority of patients received adjuvant
tamoxifen (64.0%), 13.9% received adjuvant chemotherapy
and 20.5% did not receive any form of adjuvant systemic
therapy. Surgery was the most frequent axillary treatment
(60.1%). 16.4% received axillary and supraclavicular fossa
radiotherapy as an alternative to axillary surgery, with an
additional 4.2% having lymphatic radiotherapy confined to
the supraclavicular fossa (patients with R4 positive nodes or
level III involvement). The maximum length of total follow-
up was 15 years, with a median of 8.1 years in patients who
remain alive.Reproducibility of photographic assessments
of the breast
Of the 1410 patients in the trial, 1284 had a baseline
photographic assessment and of these, 1202 have at least
one follow-up photographic assessment of late normal tissue
effects (Fig. 1). The number of pairs of photographs
available at each time point was 1128 at 1 year, 1004 at 2
years, 525 at 3 years, 472 at 4 years, 765 at 5 years, and 141
at 10 years. Reasons for non-availability were explored, and
no evidence was observed that this was associated with
either the fractionation schedule or to the probability of
experiencing a future normal tissue event or local relapse.
In the 1202 patients with baseline and at least one follow-
up photograph, a total of 4035 pairs of follow-up photo-
graphs have been assessed. Of these, 1058 caused a
discrepancy between observers, and the majority of these
discrepancies were resolved by repeat assessment. Overall,
the percentage agreement between pairs of observers was
81.3, 83.4 and 81.9% for observers 1 and 2, 1 and 3, and 2 and
3, when 62.4, 66.1 and 64.3% agreement would have been
expected by chance. These generate weighted kappa
statistics of 0.56, 0.57, 0.55, all of which are highly
significant in this large cohort. Three hundred and eightyn=271
n=396
n=422
n=465
50Gy 25Fr 5 weeks
n=470
n=266
n=397
n=428
n=456
42.9Gy 13Fr 5 weeks
n=466
n=269
n=409
n=434
n=457
39Gy 13Fr 5 weeks
n=474
n=1410Number Randomised
Fractionation Schedule 
Received allocated 
treatment
Baseline Photograph 
available
Baseline photograph  and
≥ 1 follow - up photograph
≥ 1 clinical assessment
Fig. 1. Number of patients randomised into each fractionation
schedule and with available follow-up data.
Table 2
Survival analyses of change in breast appearance and clinical assessments of late radiation effects according to fractionation schedule
Endpoint Fractionation
schedule
Events/total (%) Estimated % with no
event at 5 years
(95%CI)
Estimated % with no
event at 10 years
(95%CI)
Logrank test
comparing all 3
schedules: P-value
Photographic assessment
Any change in breast
appearance
50 Gy 140/396 (35.4) 60.4 (54.9–65.8) 46.6 (37.2–55.9) !0.001
42.9 Gy 168/397 (42.3) 54.3 (48.9–59.7) 42.0 (33.0–51.0)
39 Gy 112/409 (27.4) 69.7 (64.6–74.8) 43.9 (30.8–57.0)
Marked change in
breast appearance
50 Gy 22/396 (5.6) 93.6 (90.8–96.4) 90.2 (85.0–95.5) !0.001
42.9 Gy 40/397 (10.1) 88.8 (85.3–92.2) 84.4 (77.7–91.1)
39 Gy 14/409 (3.4) 96.1 (93.9–98.2) 93.4 (87.8–99.0)
Clinical assessment
Cosmesis (fair/poor) 50 Gy 165/271 (60.9) 44.1 (37.7–50.4) 28.8 (22.3–35.4) !0.001
42.9 Gy 175/266 (65.8) 37.9 (31.7–44.1) 25.6 (19.3–31.8)
39 Gy 136/269 (50.6) 54.6 (48.3–60.9) 42.0 (34.9–49.1)
Breast shrinkage
(moderate/marked)
50 Gy 147/271 (54.6) 49.9 (43.5–56.3) 36.2 (29.3–43.1) 0.026
42.9 Gy 148/266 (55.8) 47.2 (40.8–53.7) 34.2 (27.0–41.5)
39 Gy 124/269 (46.1) 56.9 (50.6–63.2) 44.4 (37.0–51.7)
Breast distortion
(moderate/marked)
50 Gy 132/271 (48.9) 54.6 (48.2–61.0) 41.5 (34.4–48.6) 0.005
42.9 Gy 148/266 (55.8) 45.7 (39.9–52.1) 38.0 (31.4–44.6)
39 Gy 115/269 (42.8) 59.3 (53.1–65.4) 51.4 (44.4–58.4)
Breast oedema
(moderate/marked)
50 Gy 34/271 (12.6) 87.6 (83.6–91.7) 86.2 (81.8–90.7) 0.004
42.9 Gy 54/266 (20.3) 80.2 (75.3–85.2) 78.5 (73.1–83.9)
39 Gy 29/269 (10.8) 89.4 (85.6–93.2) 88.5 (84.4–92.7)
Induration (moder-
ate/marked)
50 Gy 77/271 (28.6) 76.9 (71.5–82.3) 63.7 (56.6–70.7) !0.001
42.9 Gy 108/266 (40.8) 64.4 (58.1–70.6) 48.9 (41.5–56.4)
39 Gy 55/269 (20.4) 84.0 (79.2–88.8) 72.3 (65.5–79.2)
Telangiectasia
(moderate/marked)
50 Gy 37/271 (13.8) 88.0 (83.8–92.3) 81.9 (76.5–87.3) 0.065
42.9 Gy 38/266 (14.3) 87.0 (82.7–91.4) 82.0 (76.5–87.5)
39 Gy 23/269 (8.6) 94.4 (91.4–97.4) 88.0 (83.0–92.9)
Arm oedema (mod-
erate/marked)
50 Gy 17/271 (6.3) 93.8 (90.7–97.0) 92.3 (88.6–96.1) 0.494
42.9 Gy 22/266 (8.3) 91.7 (88.1–95.3) 89.5 (85.1–93.8)
39 Gy 16/269 (5.9) 95.4 (92.7–98.1) 93.0 (89.2–96.8)
Shoulder stiffness
(moderate/marked)
50 Gy 21/271 (7.8) 94.1 (91.2–97.0) 90.0 (85.6–94.3) !0.001
42.9 Gy 48/266 (18.1) 84.0 (79.3–88.6) 78.2 (72.3–84.0)
39 Gy 19/269 (7.1) 94.2 (91.2–97.2) 89.9 (85.3–94.6)
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Any Change in Breast Appearance
by Fractionation Schedule (n=1202)
Fig. 2. Probability of any change in breast appearance late radiation
effect ten years after radiotherapy by fractionation schedule.
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to investigate repeatability. Within-observer agreement was
78.8, 83.9 and 83.9% for observers 1, 2 and 3, respectively,
when one would expect 60.4, 61.4 and 68.2% agreement by
chance. In this case, weighted kappa statistics of 0.51, 0.61
and 0.57 are observed, each highly statistically significant.
Some variation did appear to exist between assessment
sessions but no systematic pattern has been identified.
Sensitivity of photographic assessments
to randomised dose
A total of 420 patients (34.9%) experienced some change
in breast appearance over the follow-up period, which
varied between the fractionation schedules (Table 2). Fig. 2
shows the probability of any late radiation effect over ten
years following radiotherapy, according to fractionation
schedule. There is some evidence of variation in the
difference between the fractionation schedules as follow-
up increases, as the 50 and 39 Gy arms appear to be
converging, but analysis shows this not to be statistically
significant (PZ0.08). The risk of developing any radiation
effect is much lower for patients allocated to receive 39 Gyin 13 fractions compared with those allocated 42.9 Gy in 13
fractions. There is a statistically significant difference
between the 50 and 39 Gy arms of the trial over this time
period (PZ0.01 for Logrank test), but weaker evidence for a
difference between 50 and 42.9 Gy (PZ0.05 Logrank test).
The number of patients scoring a grade 2 (marked) change in
breast appearance is relatively small, a total of 76/1202
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Marked Change in Breast Appearance
by Fractionation Schedule (n=1202)
Fig. 3. Probability of marked change in breast appearance late
radiation effect ten years after radiotherapy by fractionation
schedule.
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Breast Induration
by Fractionation Schedule (n=806)
Fig. 4. Probability of palpable breast induration ten years after
radiotherapy by fractionation schedule.
Fractionation sensitivity and dose response14patients (6.3%), but evidence is observed of a lower risk of
marked change in the patients treated with 39 Gy compared
with 42.9 Gy (see Table 2 and Fig. 3). Similarly, there is
evidence of a difference between the 50 and 42.9 Gy arms of
the trial for marked change in appearance (PZ0.01 Logrank
test), but not between 50 and 39 Gy (PZ0.18 Logrank test).
Kaplan–Meier estimates of probability of no change and no
marked change in breast appearance at 5 and 10 years,
according to treatment schedule are presented in Table 2.
The value of the a/b ratio estimated from the Cox
proportional hazards regression model for any change in
breast appearance is 3.6 Gy (95% CI 1.8–5.4 Gy), and is 2.9 Gy
(95% CI 1.0–4.8 Gy) for marked change in breast appearance,
see Table 3. The a/b values are unaltered if photographic
changes scored in the first 12 or 24 months are censored and
the analysis restricted to events emerging at R3 years (data
not shown), in order to allow for earlier, non-permanent,
changes in breast appearance due to, e.g. surgical oedema.
An estimate of the steepness of the dose-response curve
for any change in breast appearance for a fixed number of 13
fractions was derived from the 10-year estimates in Table 2
using the method by Bentzen et al. [4]. The normalised
dose-response gradient at the 50% response level, g50 was
estimated at 1.8 with (95% CI 0.8–2.7). This estimate is
obtained for otherwise unselected patients. It is likely thatTable 3
Estimates of alpha-beta ratios for each normal tissue endpoint,
obtained from Cox proportional hazards regression analysis
Endpoint a/b (95%CI), in Gy
Photographic assessment
Any change in breast appearance 3.6 (1.8–5.4)
Marked change in breast appearance 2.9 (1.0–4.8)
Clinical assessment
Cosmesis (fair/poor) 3.8 (1.4–6.3)
Breast shrinkage (moderate/marked) 4.7 (1.0–8.6)
Breast distortion (moderate/marked) 3.1 (1.0–5.8)
Breast oedema (moderate/marked) 2.3 (1.0–4.5)
Induration (moderate/marked) 3.1 (1.8–4.4)
Telangiectasia (moderate/marked) 5.1 (1.0–9.5)
Arm oedema (moderate/marked) 2.2 (1.0–7.9)
Shoulder stiffness (moderate/marked) 1.8 (1.0–3.6)the dose-response relationship would be steeper in more
homogenous subpopulations.
Clinical assessments of breast and arm
The effect of fractionation schedule on the physician
assessments of late radiation effects is shown in Table 2.
Physician assessments of overall breast cosmesis (involving
an aesthetic judgement), breast shrinkage, breast distor-
tion, breast oedema, induration and shoulder stiffness all
clearly discriminated between the 39 and 42.9 Gy treatment
arms, with a borderline effect on cutaneous telangiectasia.
Estimates of late radiation effects for the 50 Gy arm were
between those for 39 and 42.9 Gy. The effect of fraction-
ation schedule on breast induration is clearly demonstrated
in Fig. 4. The estimate of the a/b value for induration is
3.1 Gy (95% CI 1.8–4.4 Gy), as shown in Table 3. The only
clinical parameter that failed to demonstrate a dose
response between the 39 and 42.9 Gy treatment arms was
arm oedema. This is thought to reflect the small proportion
(20.6%) of patients undergoing any form of lymphatic
radiotherapy.
Effect of electron boost on breast appearance
and endpoints from clinical assessments
723 patients were randomised to boost versus no boost. A
further 687 patients were recommended an elective boost as
part of their standard treatment. The effect of boost on
photographic and clinical assessments of late radiation
effects is shown in Table 4. There were statistically
significantly reduced risks of induration and telangiectasia
(borderline) in patients randomised to no boost (see Fig. 5
for induration). Fig. 6 shows the effect of a randomised boost
on change in photographic breast appearance. The change in
breast appearance is also shown for patients treated with an
elective (non-randomised) boost.Discussion
A trial design that controls for overall treatment time
and incorporates 2 dose levels of a test regimen delivered
in 13, instead of 25, fractions offers a robust test of the
effects of fraction size on the late normal tissue responses
of the breast. The 2 test dose levels are very useful in
confirming the sensitivity of the primary endpoint (change
in breast appearance) as well as important secondary
Table 4
Survival analyses of change in breast appearance and clinical assessments of late radiation effects according to boost
Endpoint Boost Events/total (%) Estimated % with no
event at 5 years
(95%CI)
Estimated % with no
event at 10 years
(95%CI)
Logrank test
comparing all 3
schedules: P-value
Photographic assessment
Any change in
breast appearance
Rand. no boost 96/306 (31.4) 65.4 (59.4–71.3) 49.0 (35.8–62.2) 0.349
Rand. boost 117/309 (37.9) 59.2 (53.2–65.2) 46.3 (35.3–57.3)
Non-rand. boost 207/587 (35.3) 60.7 (56.2–65.2) 42.5 (34.2–50.8)
Marked change in
breast appearance
Rand. no boost 18/306 (5.9) 93.4 (90.3–96.5) 90.0 (82.9–97.1) 0.302
Rand. Boost 26/309 (8.4) 90.5 (86.9–94.1) 88.1 (82.2–93.9)
Non-rand. boost 32/587 (5.5) 93.8 (91.6–96.1) 89.7 (84.6–94.7)
Clinical assessment
Cosmesis (fair/
poor)
Rand. no boost 127/230 (55.2) 50.6 (43.8–57.3) 35.8 (28.1–43.5) 0.185
Rand. boost 138/222 (62.2) 43.0 (36.1–49.9) 29.8 (22.8–36.8)
Non-rand. boost 211/354 (59.6) 43.8 (38.3–49.4) 30.4 (24.4–36.3)
Breast shrinkage
(moderate/marked)
Rand. no boost 120/229 (52.4) 51.3 (44.4–58.2) 39.6 (32.1–47.2) 0.76
Rand. boost 123/222 (55.4) 49.2 (42.2–56.2) 34.3 (26.7–41.9)
Non-rand. boost 176/352 (50.0) 53.0 (47.3–55.8) 40.2 (33.7–46.7)
Breast distortion
(moderate/marked)
Rand. no boost 107/230 (46.5) 58.7 (52.0–65.4) 46.3 (38.5–54.0) 0.418
Rand. boost 114/222 (51.4) 52.8 (45.9–59.7) 43.5 (36.2–50.7)
Non-rand. boost 174/352 (49.4) 49.8 (44.1–55.5) 41.7 (35.4–48.0)
Breast oedema
(moderate/marked)
Rand. no boost 33/230 (14.3) 86.7 (82.3–91.1) 85.2 (80.3–90.0) 0.243
Rand. boost 40/222 (18.0) 82.7 (77.6–87.8) 81.2 (75.8–86.6)
Non-rand. boost 44/353 (12.5) 87.1 (83.4–90.8) 86.1 (82.0–90.2)
Induration (moder-
ate/marked)
Rand. no boost 50/229 (21.8) 82.8 (77.7–88.0) 72.5 (65.5–79.6) 0.001
Rand. boost 84/222 (37.8) 69.4 (63.0–75.9) 55.5 (47.8–63.1)
Non-rand. boost 106/352 (30.1) 73.9 (68.8–63.1) 58.1 (51.2–64.9)
Telangiectasia
(moderate/marked)
Rand. no boost 19/228 (8.3) 93.2 (89.8–96.7) 91.2 (87.1–95.2) 0.026
Rand. boost 38/222 (17.1) 86.9 (82.1–91.7) 77.2 (70.7–83.8)
Non-rand. boost 41/354 (11.6) 89.4 (85.8–93.0) 83.5 (78.6–88.4)
Arm swelling (mod-
erate/marked)
Rand. no boost 12/230 (5.2) 96.1 (93.4–98.8) 93.2 (89.0–97.4) 0.413
Rand. boost 16/222 (7.2) 93.3 (89.8–96.8) 91.7 (87.5–95.8)
Non-rand. boost 27/354 (7.6) 92.2 (89.1–95.3) 90.5 (86.8–94.1)
Shoulder stiffness
(moderate/marked)
Rand. no boost 27/229 (11.8) 90.6 (86.7–94.6) 85.4 (80.8–89.9) 0.873
Rand. boost 26/222 (11.7) 91.9 (88.2–95.6) 84.6 (78.8–90.4)
Non-rand. boost 35/353 (9.9) 90.1 (86.8–93.5) 87.8 (83.8–91.8)
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Fig. 5. Probability of any change in breast appearance late radiation
effect ten years after radiotherapy according to breast boost.
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levels, the 13-fraction schedule that is iso-effective with
50 Gy in 25 fractions can be determined by interpolation.
Based on these estimates, the sensitivity to fraction size
(expressed as the a/b value) can be determined directly
for several radiation-related endpoints, including change in
breast appearance and palpable induration. The a/b value
of 3.6 Gy (95% CI 1.8–5.4) for change in breast appearance
is consistent with indirect estimates of fractionation
sensitivity in a range of human non-neural late-responding
tissues [16,17]. The direct estimate of fractionation
sensitivity for marked changes in breast appearance is
very similar to this value. It is noticeable (see Fig. 2 for
example) that a clear dose response for all endpoints was
established by 12 months, but estimates of iso-effect were
not altered by confining analyses to first events scored
after 12 or 24 months.
A highly significant relationship was found between the
dose delivered in 13 fractions and the resulting change in
the incidence of changed breast appearance (PZ0.0002).
The steepness of this relationship was quantified by
the g-value and this was estimated at 1.8. Thus, a, 5%increment in total dose is estimated to cause a 9-
percentage-point increase in the proportion of patients
with marked changes in breast appearance. This illustrates
the importance of precise estimation of biologically equiv-
alent doses when modifying dose-fractionation schedules for
postoperative radiotherapy for breast cancer, in good
concordance with the published literature in this field.
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radiotherapy according to breast boost.
Fractionation sensitivity and dose response16Clinical assessments of breast induration also discrimi-
nate between the 2 test dose levels despite being performed
by a large number of clinicians over a period of many years.
The a/b value of 3.1 Gy (95% CI 1.8–4.4) for palpable
induration does not differ significantly from the photo-
graphic endpoint. Taking a conservative estimate of 3.0 Gy
for the a/b value of dose-limiting normal tissue responses in
the breast, the delivery of 39.0 in 3.0 Gy fractions over 5
weeks is iso-effective with 46.7 in 2.0 Gy equivalents
(fractions). The delivery of 42.9 in 3.3 Gy fractions over 5
weeks is iso-effective with 53.9 in 2 Gy equivalents. By
interpolation, 50 Gy in 25 fractions is iso-effective with 40.8
in 13 fractions of 3.14 Gy over 5 weeks. If the a/b value for
dose-limiting late normal tissue responses in the breast is
4.0 Gy, the 2 test regimens are equivalent to 45.5 and
52.2 Gy, respectively, in 2.0 Gy equivalents, and 50 Gy in 25
fractions is iso-effective with 41.6 Gy in 13 fractions of
3.2 Gy over 5 weeks.
In scoring change in photographic breast appearance, no
attempt was made to score cosmesis, a term which implies
an aesthetic judgement. The photographic endpoint
restricted itself to changes in size and shape of the breast
compared to the post-surgical baseline, using the contral-
ateral breast as a control for time-related changes in
appearance. Size change was dominated by shrinkage,
although a minority of women scored an event by virtue of
breast swelling at the 12 months assessment. In a proportion
of these women, swelling was related to simple breast
oedema, associated with visible linear indentations on the
skin caused by the patient’s brassiere. In others, the
overlying skin looked stretched, shiny and erythematous.
Although bacterial cellulitis or cutaneous tumour recurrence
could not be excluded on the basis of a photograph alone,
the appearances in this minority of patients were entirely
consistent with a post-radiation syndrome that presents a
few months after radiotherapy with inflammatory symptoms
and signs (breast pain and swelling, tenderness and
erythema confined within the treatment volume), and
resolves over several months [20].
Change in breast shape (distortion with nipple retraction)
was particularly noticeable after large resections from
the axillary tail or inframammary regions of the breast.
Since telangiectasia was infrequent on a photograph, being
concealed in skin folds, this feature was ignored. From the
above account, it is clear that although change in breast
appearance is a clinically valid and reproducible endpoint, itis influenced by response in more than one tissue type (skin,
subcutaneous fat, glandular epithelium, pectoral muscle).
This is not a limitation, but it serves as a reminder that there
are different radiation phenotypes to consider that lie
beyond the reach of photography, including effects on
bone and underlying lung and heart. The outcome data
generated by the clinical assessments of palpable induration
are, therefore, reassuring in generating comparable frac-
tionation sensitivities.
Although these data provide the most precise estimates to
date of the fractionation sensitivity of late normal tissue
responses in human breast, they are of limited clinical value
without estimating the fractionation sensitivity of breast
cancer. The current trial dataset has been incorporated into
the UK Standardisation of Radiotherapy (START) trial to
increase statistical power of estimating anti-tumour effect
[19]. For this reason, full publication of the current tumour
control data has not yet been authorised by the START Trial
Steering Committee. However, the tumour control data have
been presented in a published abstract, which generate an
a/b value for ipsilateral local tumour control of 4.1 Gy (95% CI
1.0–9.7) [12]. The wide confidence intervals reflect the
relatively small number of tumour-related events, but the
point estimate is entirely consistent with the hypothesis
under test in the trial. Recent results of a Canadian
randomised trial of 1100 patients report virtually identical
ipsilateral tumour recurrence rates after 50 Gy in 25 fractions
and 42.5 Gy in 16 fractions over 22 days to the whole breast
following tumour excision [18]. Assuming these two sche-
dules are truly iso-effective, and ignoring the difference in
treatment time (22 days versus 35 days), the a/b value for
tumour response is !3.0 Gy. If, however, breast cancer
response is time dependent, the implication would be that
the a/b value for tumour response is higher than 3.0 Gy.
The clinical implications for fractionation regimens will
be profound if it is reliably demonstrated that the average
fractionation sensitivity of breast cancer is similar to the
dose-limiting normal tissues of the breast. There would then
be no reason to prefer 2.0 Gy fractions, and the challenge
would be to determine the limits of hypo-fractionation. In
the meantime, it would lend strong support to the adoption
of commonly used schedules based on daily fractions of
2.67 Gy (to total doses of 40.0 or 42.5 Gy). If the a/b value
for tumour control is 4.0 Gy, 42.5 Gy in 16 fractions would be
equivalent to 47.1 in 2.0 Gy fractions in terms of tumour
control (ignoring differences in treatment time), and
equivalent to 50 in 2.0 Gy fractions in terms of late normal
tissue effects assuming an a/b value of 3.0 Gy. The 2.9 Gy
loss of anti-tumour effect is not likely to be clinically
relevant. Based on modelling of clinical data for breast
cancer control, one excess breast recurrence would occur
for every 200 women treated [2]. A potential loss of
therapeutic ratio might be offset by shortened treatment
times, less scope for tumour repopulation and more efficient
scheduling with primary surgery and adjuvant/neo-adjuvant
systemic therapies.
The results of this trial confirm that clinical assessments
and scoring changes in breast photographic appearance offer
sensitive measures of late radiation effects, although a close
relationship between these endpoints and patient self-
assessments of breast cosmesis, body image, functional
J. Yarnold et al. / Radiotherapy and Oncology 75 (2005) 9–17 17outcome and impact on quality of life cannot be assumed
[13,14]. In theory, it is possible to estimate an a/b value for
a patient-derived functional endpoint, but this is not
addressed by the current study. It is also possible that the
fractionation sensitivity of specific critical tissues including
pectoral muscle and rib cage differ from those responsible
for change in breast appearance. These obvious and
important points are addressed by the current UK START
trial that tests the safety and effectiveness of schedules
delivering fractions of greater than 2.0 Gy in women
requiring post-operative radiotherapy for early breast
cancer. In this trial, tumour control is the primary endpoint,
but detailed patient self-assessments of functional outcome
and quality of life will help to address these uncertainties. It
is likely that uncertainties relating to the effects of
hypofractionation on the heart are best addresses by
shielding or excluding this organ from the treatment volume.
Adverse effects on lung are best addressed by minimising the
volume of tissue exposed. There were no recorded cases of
brachial plexopathy in the 290 women who had radiotherapy
to the axilla and/or supraclavular fossa, but hypofractiona-
tion to these sites must be considered very carefully in view
of the high sensitivity of the brachial plexus to fraction size.
In conclusion, the fractionation sensitivities of the normal
tissues of the breast are consistent with expectations based
on the existing literature. If the fractionation sensitivity of
breast cancer is comparable, this opens the way for further
research into the applications of hypofractionation to breast
radiotherapy. Technology is now capable of exploiting
hypofractionation in interesting ways, since modulation of
fraction size across the breast is potentially superior to
modulation of fraction numberas a way of matching of
matching dose intensity to tumour recurrence risk.Acknowledgements
are due to all the patients who participated in this study.
Acknowledgements are also due to a large number of colleagues who
contributed to the design, implementation and analysis of this study
over many years, including Dr Ingela Turesson, University Hospital,
Uppsala, Sweden; Dr Mike Henk and Dr Diana Tait, Royal Marsden
Hospital, Sutton, UK; Mr Stephen Ebbs, Mayday University Hospital,
Croydon, UK; Dr Kim Benstead and Dr Sean Elyan, Gloucestershire
Oncology Centre, Cheltenham, UK. The trial was supported in part
by Marks and Spencer plc. The ICR-CTSU receives funding from
Cancer Research UK.
* Corresponding author. J. Yarnold, Academic Radiotherapy
Department, The Royal Marsden Hospital, Downs Road, Sutton,
Surrey SM2 5PT, UK. E-mail address: john.yarnold@icr.ac.uk
Received 28 July 2004; received in revised form 17 January 2005;
accepted 26 January 2005; available online 16 March 2005References
[1] Bates T. Hypofractionation and the therapeutic ratio. Int
J Radiat Oncol Biol Phys 1989;17:443.
[2] Bentzen SM. High-tech in radiation oncology: should there be a
ceiling? Int J Radiat Oncol Biol Phys 2004;58:320–30.[3] Bentzen SM, Baumann M. The linear-quadratic model in clinical
practice. In: Steel GG, editor. Basic clinical radiobiology.
London: Arnold; 2002. p. 134–46.
[4] Bentzen SM, Ruifrok AC, Thames HD. Repair capacity and
kinetics for human mucosa and epithelial tumors in the head
and neck: clinical data on the effect of changing the time
interval between multiple fractions per day in radiotherapy.
Radiother Oncol 1996;38:89–101.
[5] Brenner DJ. Hypofractionation for prostate cancer radio-
therapy-what are the issues? Int J Radiat Oncol Biol Phys
2003;57:912–4.
[6] Cohen L. Radiotherapy in breast cancer I. The dose–time
relationship theoretical considerations. Br J Radiol 1952;25:
636–42.
[7] Douglas BG. Superfractionation: its rationale and anticipated
benefits. Int J Radiat Oncol Biol Phys 1982;8:1143–53.
[8] Douglas BG, Castro JR. Novel fractionation schemes and high
linear energy transfer. Prog Exp Tumor Res 1984;28:152–65.
[9] Fletcher GH. Hypofractionation: lessons from complications.
Radiother Oncol 1991;20:10–15.
[10] Fowler JF. The linear-quadratic formula and progress in
fractionated radiotherapy. Br J Radiol 1989;62:679–94.
[11] McKinna F, Gothard L, Ashley S, et al. Selective avoidance of
lymphatic radiotherapy in the conservative management of
women with early breast cancer. Radiother Oncol 1999;52:
219–23.
[12] Owen JR, Yarnold JR, Ashton A, et al. Fractionation sensitivity
of the breast: results of a randomised trial. Eur J Oncol Suppl
2003;1:S9.
[13] Sneeuw KC, Aaronson NK, Yarnold JR, et al. Cosmetic and
functional outcomes of breast conserving treatment for early
stage breast cancer. 1. Comparison of patients’ ratings,
observers’ ratings, and objective assessments. Radiother
Oncol 1992;25:153–9.
[14] Sneeuw KC, Aaronson NK, Yarnold JR, et al. Cosmetic and
functional outcomes of breast conserving treatment for early
stage breast cancer. 2. Relationship with psychosocial func-
tioning. Radiother Oncol 1992;25:160–6.
[15] Suit H, Skates S, Taghian A, et al. Clinical implications of
heterogeneity of tumor response to radiation therapy. Radio-
ther Oncol 1992;25:251–60.
[16] Thames HD, Bentzen SM, Turesson I, et al. Time–dose factors in
radiotherapy: a review of the human data. Radiother Oncol
1990;19:219–35.
[17] Thames HD, Hendry JH, Moore JV, et al. The high steepness of
dose-response curves for late-responding normal tissues.
Radiother Oncol 1989;15:49–53.
[18] Whelan T, MacKenzie R, Julian J, et al. Randomized trial of
breast irradiation schedules after lumpectomy for women with
lymph node-negative breast cancer. J Natl Cancer Inst 2002;94:
1143–50.
[19] Winfield E, Deighton A, Venables K, et al. Survey of UK breast
radiotherapy techniques: background prior to the introduction
of the quality assurance programme for the START (standard-
isation of radiotherapy) trial in breast cancer. Clin Oncol (R Coll
Radiol) 2002;14:267–71.
[20] Winkelmann RK, Grado GL, Quimby SR, Connolly SM. Pseudo-
sclerodermatous panniculitis after irradiation: an unusual
complication of megavoltage treatment of breast carcinoma.
Mayo Clin Proc 1993;68:122–7.
[21] Yarnold J.R., Owen J.R., Ashton A., et al. Fractionation
sensitivity of change in breast appearance after radiotherapy
for early breast cancer: long-term results of a randomised trial.
Radiother Oncol 2002;64 Supplement 1:S25.
